<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group>
<journal-title>PLoS ONE</journal-title></journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PONE-D-13-07173</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0066847</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Plasma proteins</subject></subj-group></subj-group><subj-group><subject>Blood chemistry</subject><subject>Metabolism</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical immunology</subject><subj-group><subject>Immune system</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group><subj-group><subject>Immunity</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group><subj-group><subject>Clinical research design</subject><subj-group><subject>Clinical trials</subject></subj-group></subj-group><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Pathology</subject><subj-group><subject>General pathology</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group></subj-group><subj-group><subject>Drugs and devices</subject><subj-group><subject>Behavioral pharmacology</subject><subject>Clinical pharmacology</subject><subject>Psychopharmacology</subject></subj-group></subj-group><subj-group><subject>Mental health</subject><subj-group><subject>Psychiatry</subject><subj-group><subject>Mood disorders</subject></subj-group></subj-group></subj-group><subj-group><subject>Metabolic disorders</subject></subj-group></subj-group></article-categories>
<title-group>
<article-title>Inflammation’s Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naïve Patients with Bipolar II Disorder</article-title>
<alt-title alt-title-type="running-head">Cytokines &amp; Metabolic Profiles in BP-II Disorder</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lee</surname><given-names>Sheng-Yu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>Shiou-Lan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chang</surname><given-names>Yun-Hsuan</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>Po See</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Huang</surname><given-names>San-Yuan</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tzeng</surname><given-names>Nian-Sheng</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>Yu-Shan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>Liang-Jen</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lee</surname><given-names>I. Hui</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>Tzu-Yun</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yeh</surname><given-names>Tzung Lieh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yang</surname><given-names>Yen Kuang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hong</surname><given-names>Jau-Shyong</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lu</surname><given-names>Ru-Band</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Department of Psychiatry, National Cheng Kung University, Tainan, Taiwan</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Institute of Behavioral Medicine, National Cheng Kung University, Tainan, Taiwan</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>Institute of Allied Health Sciences, College of Medicine and Hospital, National Cheng Kung University, Tainan, Taiwan</addr-line></aff>
<aff id="aff4"><label>4</label><addr-line>Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan</addr-line></aff>
<aff id="aff5"><label>5</label><addr-line>Department of Child and Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan</addr-line></aff>
<aff id="aff6"><label>6</label><addr-line>Addiction Research Center, National Cheng Kung University, Tainan, Taiwan</addr-line></aff>
<aff id="aff7"><label>7</label><addr-line>Department of Psychiatry, Tainan Hospital, Department of Health, Executive Yuan, Tainan, Taiwan</addr-line></aff>
<aff id="aff8"><label>8</label><addr-line>Laboratory of Toxicology and Pharmacology, NIH/NIEHS, Research Triangle Park, North Carolina, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Mazza</surname><given-names>Marianna</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>Catholic University of Sacred Heart of Rome, Italy</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">rblu@mail.ncku.edu.tw</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: SYL RBL. Performed the experiments: SYL SLC YHC YSW. Analyzed the data: SYL SLC YHC YSW. Contributed to the reagents/materials/analysis tools: SYL SLC YHC YSW. Wrote the paper: SYL RBL PSC SYH NST. Managed participant recruitment: IHL TLY YKY. Supervised this work and edited the manuscript: JSH.</p></fn>
</author-notes>
<pub-date pub-type="collection"><year>2013</year></pub-date>
<pub-date pub-type="epub"><day>27</day><month>6</month><year>2013</year></pub-date>
<volume>8</volume>
<issue>6</issue>
<elocation-id>e66847</elocation-id>
<history>
<date date-type="received"><day>6</day><month>2</month><year>2013</year></date>
<date date-type="accepted"><day>8</day><month>5</month><year>2013</year></date>
</history>
<permissions>
<copyright-year>2013</copyright-year>
<copyright-holder>Lee et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract><sec>
<title/>
<p>Inflammation is thought to be involved in the pathophysiology of bipolar disorder (BP) and metabolic syndrome. Prior studies evaluated the association between metabolic profiles and cytokines only during certain mood states instead of their changes during treatment. We enrolled drug-naïve patients with BP-II and investigated the correlation between changes in mood symptoms and metabolic indices with changes in plasma cytokine levels after 12 weeks of pharmacological treatment. Drug-naïve patients (n = 117) diagnosed with BP-II according to DSM-IV criteria were recruited. Metabolic profiles (cholesterol, triglyceride, HbA1C, fasting serum glucose, body mass index (BMI) and plasma cytokines (TNF-α, CRP, IL-6, and TGF-β) were measured at baseline and 2, 8, and 12 weeks post-treatment. To adjust within-subject dependence over repeated assessments, multiple linear regressions with generalized estimating equation methods were used. Seventy-six (65.0%) patients completed the intervention. Changes in plasma CRP were significantly associated with changes in BMI (<italic>P</italic> = 1.7E-7) and triglyceride (<italic>P</italic> = 0.005) levels. Changes in plasma TGF-β1 were significantly associated with changes in BMI (<italic>P</italic> = 8.2E-6), cholesterol (<italic>P</italic> = 0.004), and triglyceride (<italic>P</italic> = 0.006) levels. However, changes in plasma TNF-α and IL-6 were not associated with changes in any of the metabolic indices. Changes in Hamilton Depression Rating Scale scores were significantly associated with changes in IL-6 (<italic>P</italic> = 0.003) levels; changes in Young Mania Rating Scale scores were significantly associated with changes in CRP (<italic>P</italic> = 0.006) and TNF-α (<italic>P</italic> = 0.039) levels. Plasma CRP and TGF-β1 levels were positively correlated with several metabolic indices in BP-II after 12 weeks of pharmacological intervention. We also hypothesize that clinical symptoms are correlated with certain cytokines. These new findings might be important evidence that inflammation is the pathophysiology of clinical symptoms and metabolic disturbance in BP-II.</p>
</sec><sec>
<title>Trial Registration</title>
<p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT01188148" xlink:type="simple">NCT01188148</ext-link>.</p>
</sec></abstract>
<funding-group><funding-statement>This work was supported in part by grant NSC98-2314-B-006-022-MY3 (to RBL) and NSC98-2314-B-006-022-MY3 (to SYL) from the Taiwan National Science Council, grant DOH 95-TD-M-113-055 (to RBL) from the Taiwan Department of Health, grant NHRI-EX-97-9738NI (to RBL) from the Taiwan National Health Research Institute, and the National Cheng Kung University Project for Promoting Academic Excellence and Developing World Class Research Centers. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="7"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Bipolar II disorder (BP-II), defined as recurrent episodes of depression and hypomania, is frequently misdiagnosed in clinical settings <xref ref-type="bibr" rid="pone.0066847-Akiskal1">[1]</xref>–<xref ref-type="bibr" rid="pone.0066847-Benazzi2">[4]</xref>. It is believed that BP-II is greatly under diagnosed in clinical practice and lacks in-depth research because BP-II has been regarded as a “milder form of Bipolar I disorder (BP-I)” <xref ref-type="bibr" rid="pone.0066847-Angst2">[5]</xref>, <xref ref-type="bibr" rid="pone.0066847-Vieta1">[6]</xref>. However, long-term follow-ups show that patients with BP-II have a more chronic course, more mood episodes, more major and minor depressive episodes, and shorter inter-episodes, all of which last longer than those of patients with BP-I <xref ref-type="bibr" rid="pone.0066847-Judd1">[7]</xref>–<xref ref-type="bibr" rid="pone.0066847-Vieta2">[9]</xref>. In addition, suicidal risk seems to be particularly elevated in BP-II <xref ref-type="bibr" rid="pone.0066847-Rihmer1">[10]</xref>. The high rate of suicide in BP-II may be explained by frequent misdiagnoses of the disorder followed by ineffective treatment <xref ref-type="bibr" rid="pone.0066847-Ghaemi1">[11]</xref>, <xref ref-type="bibr" rid="pone.0066847-MacQueen1">[12]</xref>.</p>
<p>Inflammation appears to be involved in the pathophysiology, phenomenology, and treatment response of BP <xref ref-type="bibr" rid="pone.0066847-Goldstein1">[13]</xref>. Activation of the inflammatory response system and increased activity of the proinflammatory cytokines interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor (TNF-α) were found during acute manic and depressive states <xref ref-type="bibr" rid="pone.0066847-Dickerson1">[14]</xref>, <xref ref-type="bibr" rid="pone.0066847-Kim1">[15]</xref> <xref ref-type="bibr" rid="pone.0066847-Knijff1">[16]</xref>–<xref ref-type="bibr" rid="pone.0066847-Soderlund1">[18]</xref>. However, whether these phenomena are state-dependent and normalize in remission remains controversial <xref ref-type="bibr" rid="pone.0066847-Boufidou1">[19]</xref>, <xref ref-type="bibr" rid="pone.0066847-Knijff2">[20]</xref>. These discrepancies may be explained by methodological differences such as heterogeneity in sample characteristics, sample size, medication received, and not controlling for known comorbidities <xref ref-type="bibr" rid="pone.0066847-Goldstein1">[13]</xref>. However, an understanding of an association between inflammation and BP might reveal novel pathophysiology and treatment options, and it might even benefit investigating using anti-inflammatory medications to treat BP <xref ref-type="bibr" rid="pone.0066847-Brietzke1">[21]</xref>, <xref ref-type="bibr" rid="pone.0066847-Nery1">[22]</xref>.</p>
<p>Patients with BP have a higher prevalence of metabolic syndrome than do the general population <xref ref-type="bibr" rid="pone.0066847-Ferguson1">[23]</xref>–<xref ref-type="bibr" rid="pone.0066847-Zarate2">[25]</xref>. Obesity is more prevalent in BP and is associated with a worse prognosis and with suicide attempts <xref ref-type="bibr" rid="pone.0066847-Fagiolini1">[26]</xref>. Several possible factors might contribute to the high risk of metabolic disturbance in patients with BP. Treatment with second-generation antipsychotics and mood stabilizers such as valproate has been associated with altered lipid profiles <xref ref-type="bibr" rid="pone.0066847-Bowden1">[27]</xref>–<xref ref-type="bibr" rid="pone.0066847-Chang1">[30]</xref>. In addition, dysfunction of the HPA axis, dysregulation of hormones, and neurotransmitters in BP might also contribute to metabolic disturbance <xref ref-type="bibr" rid="pone.0066847-Kenna1">[31]</xref>–<xref ref-type="bibr" rid="pone.0066847-Vogelzangs1">[34]</xref>.</p>
<p>It has been hypothesized that the increased risk for obesity in populations with mood disorder is a consequence of shared pathophysiological pathways. Obesity is proposed as a chronic low-grade proinflammatory state <xref ref-type="bibr" rid="pone.0066847-Karalis1">[35]</xref>; alterations in CRP and proinflammatory cytokines such as TNF-α and IL-6 are commonly reported in obesity <xref ref-type="bibr" rid="pone.0066847-Bullo1">[36]</xref>–<xref ref-type="bibr" rid="pone.0066847-Bornstein1">[38]</xref>. Increased plasma transforming growth factor (TGF)-β1, an anti-inflammatory cytokine, was correlated with dyslipidemia in an animal model <xref ref-type="bibr" rid="pone.0066847-Zhou1">[39]</xref>. Taking these findings together, the bidirectional relationship between metabolic abnormality and BP may be a consequence of aberrant inflammatory networks. Clarifying the correlation between inflammatory markers and the metabolic profile in BP is worth further investigation.</p>
<p>Most studies have evaluated only the association between metabolic disturbance and inflammatory markers during certain mood states instead of evaluating their changes over a prolonged course of treatment. In the present study, we enrolled drug-naïve patients with BP-II and measured their plasma cytokine levels and metabolic indices before and after they had undergone a 12-week pharmacological intervention. We investigated the correlation between changes in inflammatory markers and metabolic indices after 12 weeks of treatment. The correlation between changes in these inflammatory markers and in clinical symptoms was also investigated.</p>
</sec><sec id="s2" sec-type="methods">
<title>Methods</title>
<sec id="s2a">
<title>Ethic Statement</title>
<p>The research protocol was approved by the Institutional Review Board for the Protection of Human Subjects at Tri-Service General Hospital and at National Cheng Kung University Hospital. After the study protocol had been completely described to the participants, they all signed written informed consent forms before the trial started and before blood samples were drawn.</p>
</sec><sec id="s2b">
<title>Patient selection</title>
<p>This study is a subgroup analysis of a clinical trial (Trial registration: NCT01188148 at <ext-link ext-link-type="uri" xlink:href="https://register.clinicaltrials.gov/" xlink:type="simple">https://register.clinicaltrials.gov/</ext-link>). The protocol for this trial and supporting CONSORT checklist are available as supporting information; see <xref ref-type="supplementary-material" rid="pone.0066847.s001">Checklist S1</xref> and <xref ref-type="supplementary-material" rid="pone.0066847.s002">Protocol S1</xref>. The original study was a randomized, double-blind, controlled 12-week trial, aimed to investigate whether treating bipolar II disorder with valproate (VPA) plus add-on memantine is more effective than VPA alone (Lee et al., unpublished). The original study protocol was to examine 4 subgroups: VPA + placebo, VPA + memantine, VPA + placebo + cognitive behavioral group therapy, VPA + memantine + cognitive behavioral group therapy. However, because of staff shortage, we were unable to perform cognitive behavioral group therapy. Therefore, only the two groups undergoing pharmacotherapy were included in for the entire 12-week study period. Because the aim of the current study was to investigate the association between inflammation and metabolic profiles, we used only patients from the placebo group for this subgroup analysis to avoid the influence of add-on memantine, which is not a routinely used medication in the treatment of bipolar II disorder. In this way, the result would be more applicable to daily practice.</p>
<p>The study population was recruited from outpatient and inpatient settings in Tri-Service General Hospital in Taipei and at National Cheng Kung University Hospital in Tainan, Taiwan. The inclusion criteria were: a) Patients with BP-II initially evaluated in an interview by an attending psychiatrist and followed-up with a more detailed interview with a clinical psychologist using the Chinese Version of the Modified Schedule of Affective Disorder and Schizophrenia-Life Time (SADS-L) <xref ref-type="bibr" rid="pone.0066847-Endicott1">[40]</xref>, which has good inter-rater reliability <xref ref-type="bibr" rid="pone.0066847-Huang1">[41]</xref>, to determine Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnoses; b)Han Chinese; c) between 18 and 65 years old. The exclusion criteria were: 1) a major mental illness, borderline personality disorder, drug dependence, or a cognitive disorder other than BP-II; 2) previous use of any psychotropic agent; 3) taking any anti-inflammatory medication before or during the trial period.</p>
<p>Although DSM-IV-TR <xref ref-type="bibr" rid="pone.0066847-AmericanPsychiatric1">[42]</xref> criteria require a minimum duration of 4 days of hypomania, current epidemiologic data samples <xref ref-type="bibr" rid="pone.0066847-Angst1">[2]</xref>, <xref ref-type="bibr" rid="pone.0066847-Judd1">[7]</xref>, <xref ref-type="bibr" rid="pone.0066847-Akiskal2">[43]</xref>–<xref ref-type="bibr" rid="pone.0066847-Benazzi3">[46]</xref> suggest that a 2-day duration is more prevalent in the community; therefore, we used the 2-day minimum for hypomania when diagnosing BP-II.</p>
</sec><sec id="s2c">
<title>Study Design</title>
<p>After they had been enrolled in this study, the patients were given open-label valproic acid (500 mg and 1000 mg daily [50–100 μg/ml in plasma]). Only limited use of benzodiazepines (lorazepam; up to 8-mg/day) or fluoxetine (up to 20 mg/day) was allowed as concomitant medication for insomnia, agitation, or irritability. The doses were adjusted based on each patient's clinical manifestations and tolerance. In case of side-effect intolerance or clinical worsening, the patients were withdrawn earlier. The severity of mood symptoms was assessed using the Young Mania Rating Scale (YMRS) <xref ref-type="bibr" rid="pone.0066847-Young1">[47]</xref> and the Hamilton Depression Rating Scale (HDRS) <xref ref-type="bibr" rid="pone.0066847-Hamilton1">[48]</xref>, <xref ref-type="bibr" rid="pone.0066847-Hamilton2">[49]</xref>. Clinical ratings were done by research psychiatrists who were trained and experienced in using the rating scales. Symptom severity was assessed at baseline and at 2, 8, and 12 weeks. After the initiation of pharmacological treatment, BMI, lipid profile (cholesterol, triglyceride, high density lipoprotein (HDL), low density lipoprotein (LDL)), fasting serum glucose level, and glycosylated hemoglobin (HbA1C) were measured at baseline and at each visit when symptom severity was assessed.</p>
<p>Ten milliliters of whole blood was withdrawn from the antecubital vein of each patient. Plasma was isolated from the whole blood after it had been centrifuged at 3000 g for 15 min at 4°C, and then it was immediately stored at −80°C. Cytokine levels were quantified using an antibody pair assay system (Flexia; BioSource Intl., Camarillo, CA). Sample processing and data analysis were done according to the manufacturer's instructions. The immunological parameters–CRP, TNF-α, TGF-β, and IL-6–were measured at baseline and at each visit when symptom severity was assessed.</p>
</sec><sec id="s2d">
<title>Statistical Analysis</title>
<p>SPSS 18 for Windows was used for statistical computations. Significance was set at <italic>P</italic>&lt;0.05. Repeated measurements were used to investigate the association of plasma cytokine levels with the metabolic profile (BMI, lipid profile, fasting serum glucose level, and HbA1C) and symptom severity before and after pharmacological treatment. Because all cytokine levels were distributed erratically and showed a significant level of positive skew (<xref ref-type="table" rid="pone-0066847-t001">Table 1</xref>), arithmetic transformations were used to produce approximately normal distributions for further analysis; log (<italic>x</italic>+1) was used for cytokine levels. To evaluate the possible correlations of the plasma cytokines with the metabolic profile (BMI, lipid profile, fasting serum glucose level, and HbA1C) and symptom severity, the multiple linear regression model was used. The statistical method, the generalized estimating equation (GEE) <xref ref-type="bibr" rid="pone.0066847-Zeger1">[50]</xref>, was set up for multiple linear regression in repeated-measures studies which can accommodate randomly missing data <xref ref-type="bibr" rid="pone.0066847-Shen1">[51]</xref>. In the current study, GEE analysis was used to investigate the correlations of the plasma cytokines (dependent variables) with the metabolic profile and symptom severity (all parameters of which were independent variables); time effects (treatment period from baseline to week 12), gender and age were controlled for. To adjust for multiple comparisons, a Bonferroni correction for multiple comparisons was done.</p>
<table-wrap id="pone-0066847-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0066847.t001</object-id><label>Table 1</label><caption>
<title>Mean HDRS score, YMRS score, and cytokine and metabolic profiles before and after pharmacological treatment.</title>
</caption><alternatives><graphic id="pone-0066847-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0066847.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Baseline</td>
<td align="left" rowspan="1" colspan="1">After 12 Weeks</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Number (n)</td>
<td align="left" rowspan="1" colspan="1">117</td>
<td align="left" rowspan="1" colspan="1">76</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Gender (male/female) (n)</td>
<td align="left" rowspan="1" colspan="1">65/52</td>
<td align="left" rowspan="1" colspan="1">45/31</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Age, mean (SD), (years)</td>
<td align="left" rowspan="1" colspan="1">30.66±11.11</td>
<td align="left" rowspan="1" colspan="1">30.3±11.1</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Age at onset (years)</td>
<td align="left" rowspan="1" colspan="1">17.5±5.4</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Number of episodes</td>
<td align="left" rowspan="1" colspan="1">4.3±2.6</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">HDRS1 score, mean (SD)</td>
<td align="left" rowspan="1" colspan="1">19.2±5.4</td>
<td align="left" rowspan="1" colspan="1">9.4±6.5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">YMRS2score, mean (SD)</td>
<td align="left" rowspan="1" colspan="1">9.5±4.6</td>
<td align="left" rowspan="1" colspan="1">5.8±3.9</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">BMI, mean (SD), (kg/m2)</td>
<td align="left" rowspan="1" colspan="1">23.4±4.9</td>
<td align="left" rowspan="1" colspan="1">24.3±4.7</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Glucose AC, mean (SD), (mg/dL)</td>
<td align="left" rowspan="1" colspan="1">89.8±17.1</td>
<td align="left" rowspan="1" colspan="1">86.4±25.2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Triglyceride, mean (SD), (mg/dL)</td>
<td align="left" rowspan="1" colspan="1">92.2±73.3</td>
<td align="left" rowspan="1" colspan="1">97.4±64.8</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cholesterol (total), mean (SD),(mg/dL)</td>
<td align="left" rowspan="1" colspan="1">179.5±35.1</td>
<td align="left" rowspan="1" colspan="1">183.5±35.1</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">HDL-C, mean (SD), (mg/dL)</td>
<td align="left" rowspan="1" colspan="1">58.2±16.0</td>
<td align="left" rowspan="1" colspan="1">58.4±16.0</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">LDL-C, mean (SD), (mg/dL)</td>
<td align="left" rowspan="1" colspan="1">109.9±30.4</td>
<td align="left" rowspan="1" colspan="1">112.5±30.9</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">HbA1C, mean (SD), (%)</td>
<td align="left" rowspan="1" colspan="1">5.54±0.48</td>
<td align="left" rowspan="1" colspan="1">5.61±1.32</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Depakine level, mean (SD), (mg/L)</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">67.5±23.5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">CRP (ng/mL)</td>
<td align="left" rowspan="1" colspan="1">1906.6±1916.8</td>
<td align="left" rowspan="1" colspan="1">1459.5±1630.5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">TGF-β1 (pg/mL)</td>
<td align="left" rowspan="1" colspan="1">30788.9±16364.5</td>
<td align="left" rowspan="1" colspan="1">27145.3±16269.8</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">TNF-α(pg/mL)</td>
<td align="left" rowspan="1" colspan="1">1.74±1.70</td>
<td align="left" rowspan="1" colspan="1">1.63±1.80</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">IL-6 (pg/mL)</td>
<td align="left" rowspan="1" colspan="1">1.51±1.75</td>
<td align="left" rowspan="1" colspan="1">1.46±2.01</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>VPA: valproate; HDRS: Hamilton Depression Rating Scale; YMRS: Young Mania Rating Scale; CRP: C-reactive protein; TGF-β1: transforming growth factor β1; TNF-α: tumor necrosis factor α; IL-6: interleukin 6.</p></fn></table-wrap-foot></table-wrap>
<p>The power analysis was done using G-Power 3 software <xref ref-type="bibr" rid="pone.0066847-Buchner1">[52]</xref>, <xref ref-type="bibr" rid="pone.0066847-Faul1">[53]</xref>, and the effect-size conventions were determined according to Buchner et al. <xref ref-type="bibr" rid="pone.0066847-Buchner1">[52]</xref>.</p>
</sec></sec><sec id="s3">
<title>Results</title>
<p>The trial ran from 1<sup>st</sup> August, 2008 to 31<sup>st</sup> July, 2012. The first patient was recruited on 2009/8/25 while the last enrolled patient finished on 2012/5/30. One hundred seventeen patients were recruited. All patients with BP-II were first diagnosed, and that they had no history of taking mood stabilizers or antipsychotics was verified.</p>
<p>At baseline, 117 patients were assessed. One hundred and three patients were assessed when the trial proceeded to week 2. At week 8, eighty patients were assessed. In the end, seventy-six (65.0%) of the 117 patients completed the 12-week pharmacological treatment and metabolic profile survey (<xref ref-type="fig" rid="pone-0066847-g001">Figure 1</xref>) The demographic and clinical characteristics, baseline and endpoint HDRS and YMRS scores, metabolic profiles, and plasma cytokine levels of the patients are shown in <xref ref-type="table" rid="pone-0066847-t001">Table 1</xref>.</p>
<fig id="pone-0066847-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0066847.g001</object-id><label>Figure 1</label><caption>
<title>Consort flow chart of recruitment.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0066847.g001" position="float" xlink:type="simple"/></fig>
<p>Correlation analysis was done on all patients in the placebo group. Changes in plasma CRP levels were significantly associated with changes in BMI (<italic>P</italic> = 1.7E-7) and triglyceride (<italic>P</italic> = 0.005) levels (<xref ref-type="table" rid="pone-0066847-t002">Table 2</xref>). However, changes in plasma CRP levels were not associated with changes in cholesterol, HDL, LDL, or HbA1C levels. Changes in plasma TGF-β1 levels were significantly associated with changes in BMI (<italic>P</italic> = 8.2E-6), cholesterol (<italic>P</italic> = 0.004), and triglyceride (<italic>P</italic> = 0.006) levels, but not with the changes in HDL, LDL, or HbA1C levels. Changes in plasma TNF-α and IL-6 levels were not associated with any of the changes in metabolic indices after the 12-week treatment (<xref ref-type="table" rid="pone-0066847-t002">Table 2</xref>). Changes in HDRS scores were significantly associated with changes in IL-6 (<italic>P</italic> = 0.003) levels. In addition, the changes in YMRS scores were significantly associated with changes in CRP (<italic>P</italic> = 0.006) and TNF-α (<italic>P</italic> = 0.039) levels (<xref ref-type="table" rid="pone-0066847-t002">Table 2</xref>). However, if we correct for multiple comparisons, only the associations between CRP and TGF-α1 with BMI (both <italic>P&lt;</italic>0.001) remain significant.</p>
<table-wrap id="pone-0066847-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0066847.t002</object-id><label>Table 2</label><caption>
<title>Correlation of changes in metabolic profiles and cytokines before and after 12 weeks of pharmacological treatment.</title>
</caption><alternatives><graphic id="pone-0066847-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0066847.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td colspan="3" align="left" rowspan="1">CRP</td>
<td colspan="3" align="left" rowspan="1">TGF-β1</td>
<td colspan="3" align="left" rowspan="1">IL-6</td>
<td colspan="3" align="left" rowspan="1">TNF-α</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">B</td>
<td align="left" rowspan="1" colspan="1">95%CI</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic></td>
<td align="left" rowspan="1" colspan="1">B</td>
<td align="left" rowspan="1" colspan="1">95%CI</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic></td>
<td align="left" rowspan="1" colspan="1">B</td>
<td align="left" rowspan="1" colspan="1">95%CI</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic></td>
<td align="left" rowspan="1" colspan="1">B</td>
<td align="left" rowspan="1" colspan="1">95%CI</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic></td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">HDRS</td>
<td align="left" rowspan="1" colspan="1">0.624</td>
<td align="left" rowspan="1" colspan="1">−0.28–1.53</td>
<td align="left" rowspan="1" colspan="1">0.176</td>
<td align="left" rowspan="1" colspan="1">0.062</td>
<td align="left" rowspan="1" colspan="1">−1.58–1.70</td>
<td align="left" rowspan="1" colspan="1">0.941</td>
<td align="left" rowspan="1" colspan="1">2.41</td>
<td align="left" rowspan="1" colspan="1">0.81–4.0</td>
<td align="left" rowspan="1" colspan="1">0.003</td>
<td align="left" rowspan="1" colspan="1">0.027</td>
<td align="left" rowspan="1" colspan="1">−1.31–1.37</td>
<td align="left" rowspan="1" colspan="1">0.969</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">YMRS</td>
<td align="left" rowspan="1" colspan="1">0.958</td>
<td align="left" rowspan="1" colspan="1">0.28–1.64</td>
<td align="left" rowspan="1" colspan="1">0.006</td>
<td align="left" rowspan="1" colspan="1">−0.47</td>
<td align="left" rowspan="1" colspan="1">−1.62–0.67</td>
<td align="left" rowspan="1" colspan="1">0.416</td>
<td align="left" rowspan="1" colspan="1">0.034</td>
<td align="left" rowspan="1" colspan="1">−0.70–0.77</td>
<td align="left" rowspan="1" colspan="1">0.929</td>
<td align="left" rowspan="1" colspan="1">0.62</td>
<td align="left" rowspan="1" colspan="1">0.03–1.21</td>
<td align="left" rowspan="1" colspan="1">0.039</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Triglyceride</td>
<td align="left" rowspan="1" colspan="1">28.03</td>
<td align="left" rowspan="1" colspan="1">8.6–47.5</td>
<td align="left" rowspan="1" colspan="1">0.005</td>
<td align="left" rowspan="1" colspan="1">30.98</td>
<td align="left" rowspan="1" colspan="1">8.9–53.0</td>
<td align="left" rowspan="1" colspan="1">0.006</td>
<td align="left" rowspan="1" colspan="1">14.14</td>
<td align="left" rowspan="1" colspan="1">−2.3–30.6</td>
<td align="left" rowspan="1" colspan="1">0.092</td>
<td align="left" rowspan="1" colspan="1">−0.066</td>
<td align="left" rowspan="1" colspan="1">−12.6–12.5</td>
<td align="left" rowspan="1" colspan="1">0.992</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cholesterol</td>
<td align="left" rowspan="1" colspan="1">−3.571</td>
<td align="left" rowspan="1" colspan="1">−9.3–2.2</td>
<td align="left" rowspan="1" colspan="1">0.223</td>
<td align="left" rowspan="1" colspan="1">13.36</td>
<td align="left" rowspan="1" colspan="1">4.3–22.5</td>
<td align="left" rowspan="1" colspan="1">0.004</td>
<td align="left" rowspan="1" colspan="1">−2.21</td>
<td align="left" rowspan="1" colspan="1">−8.0–3.6</td>
<td align="left" rowspan="1" colspan="1">0.457</td>
<td align="left" rowspan="1" colspan="1">−2.215</td>
<td align="left" rowspan="1" colspan="1">−8.3–3.9</td>
<td align="left" rowspan="1" colspan="1">0.478</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">HDL</td>
<td align="left" rowspan="1" colspan="1">−4.203</td>
<td align="left" rowspan="1" colspan="1">−8.7–0.3</td>
<td align="left" rowspan="1" colspan="1">0.067</td>
<td align="left" rowspan="1" colspan="1">1.07</td>
<td align="left" rowspan="1" colspan="1">−7.5–9.7</td>
<td align="left" rowspan="1" colspan="1">0.807</td>
<td align="left" rowspan="1" colspan="1">8.73</td>
<td align="left" rowspan="1" colspan="1">−0.7–18.1</td>
<td align="left" rowspan="1" colspan="1">0.070</td>
<td align="left" rowspan="1" colspan="1">−0.511</td>
<td align="left" rowspan="1" colspan="1">−3.4–4.4</td>
<td align="left" rowspan="1" colspan="1">0.799</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">LDL</td>
<td align="left" rowspan="1" colspan="1">−4.682</td>
<td align="left" rowspan="1" colspan="1">−12.1–2.8</td>
<td align="left" rowspan="1" colspan="1">0.220</td>
<td align="left" rowspan="1" colspan="1">12.4</td>
<td align="left" rowspan="1" colspan="1">−2.2–27.0</td>
<td align="left" rowspan="1" colspan="1">0.095</td>
<td align="left" rowspan="1" colspan="1">0.73</td>
<td align="left" rowspan="1" colspan="1">−8.4–9.8</td>
<td align="left" rowspan="1" colspan="1">0.876</td>
<td align="left" rowspan="1" colspan="1">−4.366</td>
<td align="left" rowspan="1" colspan="1">−12.8–4.0</td>
<td align="left" rowspan="1" colspan="1">0.308</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">BMI</td>
<td align="left" rowspan="1" colspan="1">3.23</td>
<td align="left" rowspan="1" colspan="1">2.0–4.4</td>
<td align="left" rowspan="1" colspan="1">1.7E–7<xref ref-type="table-fn" rid="nt103">**</xref></td>
<td align="left" rowspan="1" colspan="1">5.27</td>
<td align="left" rowspan="1" colspan="1">3.0–7.6</td>
<td align="left" rowspan="1" colspan="1">8.2E–6<xref ref-type="table-fn" rid="nt103">**</xref></td>
<td align="left" rowspan="1" colspan="1">−0.067</td>
<td align="left" rowspan="1" colspan="1">−0.3–0.2</td>
<td align="left" rowspan="1" colspan="1">0.589</td>
<td align="left" rowspan="1" colspan="1">−0.088</td>
<td align="left" rowspan="1" colspan="1">−0.92–0.27</td>
<td align="left" rowspan="1" colspan="1">0.285</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">HbA1C</td>
<td align="left" rowspan="1" colspan="1">0.032</td>
<td align="left" rowspan="1" colspan="1">−0.04–0.11</td>
<td align="left" rowspan="1" colspan="1">0.408</td>
<td align="left" rowspan="1" colspan="1">0.042</td>
<td align="left" rowspan="1" colspan="1">−0.03–0.12</td>
<td align="left" rowspan="1" colspan="1">0.283</td>
<td align="left" rowspan="1" colspan="1">0.034</td>
<td align="left" rowspan="1" colspan="1">−0.02–0.09</td>
<td align="left" rowspan="1" colspan="1">0.233</td>
<td align="left" rowspan="1" colspan="1">0.024</td>
<td align="left" rowspan="1" colspan="1">−0.05–0.95</td>
<td align="left" rowspan="1" colspan="1">0.505</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt102"><label/><p>CRP: C-reactive protein; TGF-β1: transforming growth factor β1; TNF-α: tumor necrosis factor α; IL-6: interleukin 6.</p></fn><fn id="nt103"><label>**</label><p><bold><italic>P</italic></bold>&lt;0.001.</p></fn></table-wrap-foot></table-wrap>
<p>The study had a power of approximately 0.33 to detect a small effect, and 0.99 to detect medium and large effects for multiple regression analysis (<italic>N</italic> = 117). In this power analysis, the effect-size conventions were determined according to Buchner et al. <xref ref-type="bibr" rid="pone.0066847-Buchner1">[52]</xref> as follows: small effect size  = 0.02, medium effect size  = 0.15, large effect size  = 0.35 for the multiple regression model (alpha  = 0.05).</p>
</sec><sec id="s4">
<title>Discussion</title>
<p>We found an association between changes in BMI and CRP, one of the markers of low-grade inflammation. This might mean that elevated levels of CRP are also indicators of a relative increase in BMI. The positive association between CRP and BMI is widely known <xref ref-type="bibr" rid="pone.0066847-Visser1">[54]</xref>–<xref ref-type="bibr" rid="pone.0066847-Zimmet1">[57]</xref> in healthy controls and other populations (diabetes, hypertension). A significant association between high CRP and prevalence of metabolic syndrome has been reported <xref ref-type="bibr" rid="pone.0066847-VuksanCusa1">[58]</xref>. Another study <xref ref-type="bibr" rid="pone.0066847-Saltevo1">[59]</xref> also reported that elevated levels of CRP in adulthood are related to changes in BMI between childhood and adulthood <xref ref-type="bibr" rid="pone.0066847-Saltevo1">[59]</xref>. Our findings about the positive association between the longitudinal changes in BMI and CRP support a positive association of BMI and CRP in drug naïve patients with BP-II. In addition, we also report a possible positive association of change in CRP and triglyceride levels which did not survive the correction of multiple comparisons. Whether this finding supports past studies <xref ref-type="bibr" rid="pone.0066847-Grundy1">[60]</xref>–<xref ref-type="bibr" rid="pone.0066847-Verma1">[62]</xref> that suggest the probable involvement of CRP with metabolic syndrome and obesity still requires further study.</p>
<p>CRP is an acute-phase reactant synthesized in the liver largely in response to proinflammatory cytokines. Adipose tissue can produce proinflammatory cytokines that subsequently increase CRP production <xref ref-type="bibr" rid="pone.0066847-MohamedAli1">[63]</xref>. CRP does not cross the blood-brain barrier (BBB) in trace amounts; however, during systemic inflammation and obesity, CRP may increase paracellular permeability of the BBB and impair BBB function <xref ref-type="bibr" rid="pone.0066847-Hsuchou1">[64]</xref>. In addition, the level of CRP may indicate the status of inflammation in the brain, which might decrease neurotrophic support and lead to brain dysfunction <xref ref-type="bibr" rid="pone.0066847-Zhu1">[65]</xref>; such dysfunction is also associated with the pathogenesis of BP. Our findings support the hypothesis that inflammation is the common underlying pathogenesis for the frequently comorbid BP and metabolic disturbances.</p>
<p>The current study also provided initial evidence of a positive correlation between TGF-β1 and and BMI. TGF-β1 induces plasminogen activator inhibitor 1 (PAI-1) synthesis and is associated with BMI in humans <xref ref-type="bibr" rid="pone.0066847-Alessi1">[66]</xref>, <xref ref-type="bibr" rid="pone.0066847-Porreca1">[67]</xref>. However, our findings of the positive correlation between TGF-β and triglycerides and cholesterol did not survive the correction of a multiple comparison. TGF-β1 is a potent anti-inflammatory cytokine that regulates various physiological processes, including cell proliferation, cell differentiation, extracellular matrix synthesis, and the immune response. It has been implicated in the pathogenesis of autoimmune disease, carcinogenesis, and cardiovascular disease <xref ref-type="bibr" rid="pone.0066847-Grainger1">[68]</xref>–<xref ref-type="bibr" rid="pone.0066847-Massague1">[70]</xref>. Evidence indicates that TGF-β is implicated in significantly higher cardiovascular disease plasma levels of activated TGF-β in patients with coronary heart disease <xref ref-type="bibr" rid="pone.0066847-Wang1">[71]</xref>. The correlation between hypercholesterolemia and TGF-β1 has been hypothesized to be caused by activation of the innate immune response, inflammation, and fibrosis <xref ref-type="bibr" rid="pone.0066847-Zhou1">[39]</xref>.Our findings confirmed a positive association between BMI and increased plasma TGF-β1in BP-II. Combining the positive association of plasma CRP and TGF-β1 with BMI and possibly dyslipidemia, we propose that the positive association is a result of activation of the immune response, which warrants study of the mechanisms involved.</p>
<p>However, we found no significant association of the metabolic profile with plasma IL-6 and TNF-α levels, as was previously reported <xref ref-type="bibr" rid="pone.0066847-MarquesVidal1">[56]</xref>, <xref ref-type="bibr" rid="pone.0066847-Moon1">[72]</xref>. This inconsistency may be explained by different study designs and the study participants in the current study. We analyzed the association of changes in metabolic profiles and inflammatory factors instead of cross-sectional correlations, as was done in previous studies. In addition, all participants in the current study were drug naïve patients with BP-II undergoing initial short-term pharmacological intervention. The long-term metabolic influences and their association with the inflammatory factors in our patients require additionalfollow-up and investigation.</p>
<p>In treating neuropsychiatric disorders, being able to identify and quantify peripheral biomarkers for diagnosis or monitoring treatment responses still remains a clinical goal. We reported that the decreases in HDRS scores over the study period were associated with decreases in IL-6 levels, and that the decreases in YMRS scores were associated with the decreases in CRP and TNF-α levels. However, these findings did not survive correction for multiple comparisons. Based on our findings, we propose that changes the levels of plasma cytokines may be associated with the severity of mood symptoms in patients with BP-II in a prolonged course of treatment instead of in a cross-sectional study. Other studies <xref ref-type="bibr" rid="pone.0066847-Kim1">[15]</xref>, <xref ref-type="bibr" rid="pone.0066847-OBrien1">[17]</xref> have suggested that changes in proinflammatory cytokines may be related to the pathophysiology of BP and to the response to pharmacological treatment. A change in IL-6 levels according to mood state is one of the most consistent findings in BP <xref ref-type="bibr" rid="pone.0066847-Kim1">[15]</xref>, <xref ref-type="bibr" rid="pone.0066847-Knijff1">[16]</xref>. Our finding supports a report <xref ref-type="bibr" rid="pone.0066847-Brietzke2">[73]</xref> that IL-6 was positively correlated with HDRS scores. In addition, our data suggest that changes plasma CRP may be associated with the severity of manic symptoms, which agrees with Dickerson et al. <xref ref-type="bibr" rid="pone.0066847-Dickerson1">[14]</xref>, who said that mania symptoms but not HDRS scores were associated with the increased production of CRP. The possible association between cytokines and clinical symptoms found in the current study requires additional study to confirm. In addition, whether the combination of these cytokines may be used as biomarkers for the severity of BP-II still requires further investigation using a larger sample size.</p>
<p>Our study has some limitations. First, we measured plasma cytokines in the current study because previous studies suggested that changes in peripheral cytokine expression levels may partially reflect the changes in peripheral levels. However, we were unable to draw a definitive conclusion about this hypothesis <xref ref-type="bibr" rid="pone.0066847-Pan1">[74]</xref>. Second, except for the correlation between changes in CRP and TNF-α with changes in BMI, most of our positive findings did not survive correction for multiple testing. Further studies with larger samples are needed to verify our results. To achieve enough power (0.8) for detection of small effect (0.02), we would need a target size around N = 395. Third, it is possible that the medication permitted in the study obscured the mood correlation between cytokines and metabolic indices. Although we tried to limit concomitant treatment medication to only three drugs, our results should still be taken with caution. Fourth, the 2-day duration for hypomania used in the current study is not widely accepted. The positive finding in the current study may not apply to patients with BP-II diagnosed according to the DSM-IV-TR criteria of the 4-day duration for hypomania. Fifth, we did not control for the baseline severity of patients. Unlike past studies that focused on only one pole of the mood spectrum, we assessed both the YMRS and HDRS scores for subsyndromal manic symptoms that were presented in over half of bipolar depressive episodes yet frequently not assessed <xref ref-type="bibr" rid="pone.0066847-Goldberg1">[75]</xref>. By evaluating symptoms on both poles of the mood spectrum, our clinical evaluation is more comprehensive, which may better reflect the association of cytokines and the symptoms of BP. Finally, our study focused only on the metabolic influences after short-term pharmacological intervention. The long-term metabolic influences in our patients require additional follow-up and investigation.</p>
<p>In conclusion, our study provides initial evidence of a positive correlation between plasma CRP and TGF-β1 levels and BMI in drug-naïve patients with BP-II after 12 weeks of pharmacological intervention. The specific roles of cytokines in regulating and maintaining peripheral metabolic health require additional investigation. We also hypothesize that clinical symptoms are correlated with certain cytokines. Whether these cytokines can be used as biomarker of BP-II warrants additional studies. We expect that knowledge of the function of plasma cytokines in metabolic disturbances will benefit the development of novel therapies to modify cytokine levels in order to control both clinical symptoms and metabolic disturbances in BP-II.</p>
</sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pone.0066847.s001" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0066847.s001" position="float" xlink:type="simple"><label>Checklist S1</label><caption>
<p><bold>CONSORT Checklist.</bold></p>
<p>(DOC)</p>
</caption></supplementary-material><supplementary-material id="pone.0066847.s002" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0066847.s002" position="float" xlink:type="simple"><label>Protocol S1</label><caption>
<p><bold>Trial Protocol.</bold></p>
<p>(DOC)</p>
</caption></supplementary-material></sec></body>
<back><ref-list>
<title>References</title>
<ref id="pone.0066847-Akiskal1"><label>1</label>
<mixed-citation publication-type="other" xlink:type="simple">Akiskal HS, Pinto O (1999) The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am 22: 517–534, vii.</mixed-citation>
</ref>
<ref id="pone.0066847-Angst1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Angst</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gamma</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sellaro</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lavori</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name> (<year>2003</year>) <article-title>Recurrence of bipolar disorders and major depression. A life-long perspective</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source> <volume>253</volume>: <fpage>236</fpage>–<lpage>240</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Benazzi1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Benazzi</surname><given-names>F</given-names></name> (<year>2001</year>) <article-title>Bipolar II depression in late life: prevalence and clinical features in 525 depressed outpatients</article-title>. <source>J Affect Disord</source> <volume>66</volume>: <fpage>13</fpage>–<lpage>18</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Benazzi2"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Benazzi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Akiskal</surname><given-names>HS</given-names></name> (<year>2003</year>) <article-title>Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania</article-title>. <source>J Affect Disord</source> <volume>73</volume>: <fpage>33</fpage>–<lpage>38</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Angst2"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Angst</surname><given-names>J</given-names></name> (<year>2007</year>) <article-title>The bipolar spectrum</article-title>. <source>Br J Psychiatry</source> <volume>190</volume>: <fpage>189</fpage>–<lpage>191</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Vieta1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vieta</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Suppes</surname><given-names>T</given-names></name> (<year>2008</year>) <article-title>Bipolar II disorder: arguments for and against a distinct diagnostic entity</article-title>. <source>Bipolar Disord</source> <volume>10</volume>: <fpage>163</fpage>–<lpage>178</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Judd1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Judd</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Akiskal</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Schettler</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Coryell</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Maser</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders?</article-title> <source>J Affect Disord</source> <volume>73</volume>: <fpage>19</fpage>–<lpage>32</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Pallanti1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pallanti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Quercioli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Pazzagli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rossi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dell'Osso</surname><given-names>L</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder</article-title>. <source>Am J Psychiatry</source> <volume>156</volume>: <fpage>1094</fpage>–<lpage>1096</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Vieta2"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vieta</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Gastó</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Otero</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nieto</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Vallejo</surname><given-names>J</given-names></name> (<year>1997</year>) <article-title>Differential features between bipolar I and bipolar II disorder</article-title>. <source>Comprehensive Psychiatry</source> <volume>38</volume>: <fpage>98</fpage>–<lpage>101</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Rihmer1"><label>10</label>
<mixed-citation publication-type="other" xlink:type="simple">Rihmer Z, Pestality P (1999) Bipolar II disorder and suicidal behavior. Psychiatr Clin North Am 22: 667–673, ix–x.</mixed-citation>
</ref>
<ref id="pone.0066847-Ghaemi1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ghaemi</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Boiman</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Goodwin</surname><given-names>FK</given-names></name> (<year>2000</year>) <article-title>Insight and outcome in bipolar, unipolar, and anxiety disorders</article-title>. <source>Compr Psychiatry</source> <volume>41</volume>: <fpage>167</fpage>–<lpage>171</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-MacQueen1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>MacQueen</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>LT</given-names></name> (<year>2001</year>) <article-title>Bipolar II disorder: symptoms, course, and response to treatment</article-title>. <source>Psychiatr Serv</source> <volume>52</volume>: <fpage>358</fpage>–<lpage>361</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Goldstein1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goldstein</surname><given-names>BI</given-names></name>, <name name-style="western"><surname>Kemp</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Soczynska</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>McIntyre</surname><given-names>RS</given-names></name> (<year>2009</year>) <article-title>Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature</article-title>. <source>J Clin Psychiatry</source> <volume>70</volume>: <fpage>1078</fpage>–<lpage>1090</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Dickerson1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dickerson</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Stallings</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Origoni</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Boronow</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yolken</surname><given-names>R</given-names></name> (<year>2007</year>) <article-title>Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>31</volume>: <fpage>952</fpage>–<lpage>955</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Kim1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname><given-names>YK</given-names></name>, <name name-style="western"><surname>Jung</surname><given-names>HG</given-names></name>, <name name-style="western"><surname>Myint</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>SH</given-names></name> (<year>2007</year>) <article-title>Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder</article-title>. <source>J Affect Disord</source> <volume>104</volume>: <fpage>91</fpage>–<lpage>95</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Knijff1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Knijff</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Breunis</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Kupka</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>de Wit</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Ruwhof</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment</article-title>. <source>Bipolar Disord</source> <volume>9</volume>: <fpage>743</fpage>–<lpage>753</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-OBrien1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>O'Brien</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Scully</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>Dinan</surname><given-names>TG</given-names></name> (<year>2006</year>) <article-title>Cytokine profiles in bipolar affective disorder: focus on acutely ill patients</article-title>. <source>J Affect Disord</source> <volume>90</volume>: <fpage>263</fpage>–<lpage>267</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Soderlund1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Soderlund</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Olsson</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Samuelsson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Walther-Jallow</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Johansson</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder</article-title>. <source>J Psychiatry Neurosci</source> <volume>36</volume>: <fpage>114</fpage>–<lpage>118</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Boufidou1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boufidou</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Nikolaou</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Alevizos</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Liappas</surname><given-names>IA</given-names></name>, <name name-style="western"><surname>Christodoulou</surname><given-names>GN</given-names></name> (<year>2004</year>) <article-title>Cytokine production in bipolar affective disorder patients under lithium treatment</article-title>. <source>J Affect Disord</source> <volume>82</volume>: <fpage>309</fpage>–<lpage>313</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Knijff2"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Knijff</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Ruwhof</surname><given-names>C</given-names></name>, <name name-style="western"><surname>de Wit</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Kupka</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Vonk</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Monocyte-derived dendritic cells in bipolar disorder</article-title>. <source>Biol Psychiatry</source> <volume>59</volume>: <fpage>317</fpage>–<lpage>326</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Brietzke1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brietzke</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kapczinski</surname><given-names>F</given-names></name> (<year>2008</year>) <article-title>TNF-alpha as a molecular target in bipolar disorder</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>32</volume>: <fpage>1355</fpage>–<lpage>1361</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Nery1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nery</surname><given-names>FG</given-names></name>, <name name-style="western"><surname>Monkul</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Hatch</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Fonseca</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zunta-Soares</surname><given-names>GB</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study</article-title>. <source>Hum Psychopharmacol</source> <volume>23</volume>: <fpage>87</fpage>–<lpage>94</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Ferguson1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ferguson</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Shingleton</surname><given-names>RN</given-names></name> (<year>2007</year>) <article-title>An open-label, flexible-dose study of memantine in major depressive disorder</article-title>. <source>Clin Neuropharmacol</source> <volume>30</volume>: <fpage>136</fpage>–<lpage>144</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Zarate1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Singh</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Carlson</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Brutsche</surname><given-names>NE</given-names></name>, <name name-style="western"><surname>Ameli</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression</article-title>. <source>Arch Gen Psychiatry</source> <volume>63</volume>: <fpage>856</fpage>–<lpage>864</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Zarate2"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zarate</surname><given-names>CA</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Singh</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Quiroz</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>De Jesus</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Denicoff</surname><given-names>KK</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>A double-blind, placebo-controlled study of memantine in the treatment of major depression</article-title>. <source>Am J Psychiatry</source> <volume>163</volume>: <fpage>153</fpage>–<lpage>155</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Fagiolini1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fagiolini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Frank</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Turkin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kupfer</surname><given-names>DJ</given-names></name> (<year>2005</year>) <article-title>Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians</article-title>. <source>Bipolar Disord</source> <volume>7</volume>: <fpage>424</fpage>–<lpage>430</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Bowden1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bowden</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Calabrese</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>McElroy</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Gyulai</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wassef</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group</article-title>. <source>Arch Gen Psychiatry</source> <volume>57</volume>: <fpage>481</fpage>–<lpage>489</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Reynolds1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Reynolds</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Sisk</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Rasgon</surname><given-names>NL</given-names></name> (<year>2007</year>) <article-title>Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review</article-title>. <source>Curr Med Chem</source> <volume>14</volume>: <fpage>2799</fpage>–<lpage>2812</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Elmslie1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Elmslie</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Porter</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Joyce</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Hunt</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Shand</surname><given-names>BI</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls</article-title>. <source>Aust N Z J Psychiatry</source> <volume>43</volume>: <fpage>53</fpage>–<lpage>60</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Chang1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chang</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>YK</given-names></name>, <name name-style="western"><surname>Gean</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>PS</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>The role of valproate in metabolic disturbances in bipolar disorder patients</article-title>. <source>J Affect Disord</source> <volume>124</volume>: <fpage>319</fpage>–<lpage>323</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Kenna1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kenna</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Rasgon</surname><given-names>NL</given-names></name> (<year>2009</year>) <article-title>Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment</article-title>. <source>Harv Rev Psychiatry</source> <volume>17</volume>: <fpage>138</fpage>–<lpage>146</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Steen1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Steen</surname><given-names>NE</given-names></name>, <name name-style="western"><surname>Methlie</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lorentzen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hope</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Barrett</surname><given-names>EA</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability?</article-title> <source>J Clin Psychiatry</source> <volume>72</volume>: <fpage>1515</fpage>–<lpage>1521</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Taylor1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Taylor</surname><given-names>V</given-names></name>, <name name-style="western"><surname>MacQueen</surname><given-names>G</given-names></name> (<year>2006</year>) <article-title>Associations between bipolar disorder and metabolic syndrome: A review</article-title>. <source>J Clin Psychiatry</source> <volume>67</volume>: <fpage>1034</fpage>–<lpage>1041</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Vogelzangs1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vogelzangs</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Penninx</surname><given-names>BW</given-names></name> (<year>2011</year>) <article-title>[Depressive symptoms, cortisol, visceral fat and metabolic syndrome]</article-title>. <source>Tijdschr Psychiatr</source> <volume>53</volume>: <fpage>613</fpage>–<lpage>620</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Karalis1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Karalis</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Giannogonas</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kodela</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Koutmani</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zoumakis</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Mechanisms of obesity and related pathology: linking immune responses to metabolic stress</article-title>. <source>FEBS J</source> <volume>276</volume>: <fpage>5747</fpage>–<lpage>5754</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Bullo1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bullo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Garcia-Lorda</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Megias</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Salas-Salvado</surname><given-names>J</given-names></name> (<year>2003</year>) <article-title>Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression</article-title>. <source>Obes Res</source> <volume>11</volume>: <fpage>525</fpage>–<lpage>531</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Das1"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Das</surname><given-names>UN</given-names></name> (<year>2001</year>) <article-title>Is obesity an inflammatory condition?</article-title> <source>Nutrition</source> <volume>17</volume>: <fpage>953</fpage>–<lpage>966</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Bornstein1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bornstein</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Schuppenies</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Licinio</surname><given-names>J</given-names></name> (<year>2006</year>) <article-title>Approaching the shared biology of obesity and depression: the stress axis as the locus of gene-environment interactions</article-title>. <source>Mol Psychiatry</source> <volume>11</volume>: <fpage>892</fpage>–<lpage>902</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Zhou1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Johnston</surname><given-names>TP</given-names></name>, <name name-style="western"><surname>Johansson</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Parini</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Funa</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Hypercholesterolemia leads to elevated TGF-beta1 activity and T helper 3-dependent autoimmune responses in atherosclerotic mice</article-title>. <source>Atherosclerosis</source> <volume>204</volume>: <fpage>381</fpage>–<lpage>387</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Endicott1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Endicott</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Spitzer</surname><given-names>RL</given-names></name> (<year>1978</year>) <article-title>A diagnostic interview: the schedule for affective disorders and schizophrenia</article-title>. <source>Arch Gen Psychiatry</source> <volume>35</volume>: <fpage>837</fpage>–<lpage>844</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Huang1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Ko</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>TJ</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence</article-title>. <source>Alcohol Clin Exp Res</source> <volume>28</volume>: <fpage>374</fpage>–<lpage>384</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-AmericanPsychiatric1"><label>42</label>
<mixed-citation publication-type="other" xlink:type="simple">American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorder-IV-TR. Washington: American Psychiatric Association.</mixed-citation>
</ref>
<ref id="pone.0066847-Akiskal2"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Akiskal</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Djenderedjian</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Rosenthal</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Khani</surname><given-names>MK</given-names></name> (<year>1977</year>) <article-title>Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group</article-title>. <source>Am J Psychiatry</source> <volume>134</volume>: <fpage>1227</fpage>–<lpage>1233</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Akiskal3"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Akiskal</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Rosenthal</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Rosenthal</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Kashgarian</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Khani</surname><given-names>MK</given-names></name>, <etal>et al</etal>. (<year>1979</year>) <article-title>Differentiation of primary affective illness from situational, symptomatic, and secondary depressions</article-title>. <source>Arch Gen Psychiatry</source> <volume>36</volume>: <fpage>635</fpage>–<lpage>643</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Angst3"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Angst</surname><given-names>J</given-names></name> (<year>1998</year>) <article-title>The emerging epidemiology of hypomania and bipolar II disorder</article-title>. <source>J Affect Disord</source> <volume>50</volume>: <fpage>143</fpage>–<lpage>151</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Benazzi3"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Benazzi</surname><given-names>F</given-names></name> (<year>2001</year>) <article-title>Is 4 days the minimum duration of hypomania in bipolar II disorder?</article-title> <source>Eur Arch Psychiatry Clin Neurosci</source> <volume>25</volume>: <fpage>32</fpage>–<lpage>34</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Young1"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Young</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Biggs</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Ziegler</surname><given-names>VE</given-names></name>, <name name-style="western"><surname>Meyer</surname><given-names>DA</given-names></name> (<year>1978</year>) <article-title>A rating scale for mania: reliability, validity and sensitivity</article-title>. <source>Br J Psychiatry</source> <volume>133</volume>: <fpage>429</fpage>–<lpage>435</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Hamilton1"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hamilton</surname><given-names>M</given-names></name> (<year>1960</year>) <article-title>A rating scale for depression</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <volume>23</volume>: <fpage>56</fpage>–<lpage>62</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Hamilton2"><label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hamilton</surname><given-names>M</given-names></name> (<year>1967</year>) <article-title>Development of a rating scale for primary depressive illness</article-title>. <source>Br J Soc Clin Psychol</source> <volume>6</volume>: <fpage>278</fpage>–<lpage>296</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Zeger1"><label>50</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zeger</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>KY</given-names></name>, <name name-style="western"><surname>Albert</surname><given-names>PS</given-names></name> (<year>1988</year>) <article-title>Models for longitudinal data: a generalized estimating equation approach</article-title>. <source>Biometrics</source> <volume>44</volume>: <fpage>1049</fpage>–<lpage>1060</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Shen1"><label>51</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shen</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>YH</given-names></name> (<year>2012</year>) <article-title>Model selection for generalized estimating equations accommodating dropout missingness</article-title>. <source>Biometrics</source> <volume>68</volume>: <fpage>1046</fpage>–<lpage>1054</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Buchner1"><label>52</label>
<mixed-citation publication-type="other" xlink:type="simple">Buchner A, Faul F, Erdfelder E (1996) G-power: A Priori, Post Hoc, and Compromise Power Analyses for the Macintosh. Version 2.1.1. ed. Germany.: University of Trier, Trier.</mixed-citation>
</ref>
<ref id="pone.0066847-Faul1"><label>53</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Faul</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Erdfelder</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Buchner</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>A</given-names></name> (<year>2009</year>) <article-title>Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses</article-title>. <source>Behav Res Methods</source> <volume>41</volume>: <fpage>1149</fpage>–<lpage>1160</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Visser1"><label>54</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Visser</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bouter</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>McQuillan</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Wener</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>TB</given-names></name> (<year>1999</year>) <article-title>Elevated C-reactive protein levels in overweight and obese adults</article-title>. <source>JAMA</source> <volume>282</volume>: <fpage>2131</fpage>–<lpage>2135</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Bermudez1"><label>55</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bermudez</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Ridker</surname><given-names>PM</given-names></name> (<year>2002</year>) <article-title>C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease</article-title>. <source>Prev Cardiol</source> <volume>5</volume>: <fpage>42</fpage>–<lpage>46</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-MarquesVidal1"><label>56</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Marques-Vidal</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Velho</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Waterworth</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Waeber</surname><given-names>G</given-names></name>, <name name-style="western"><surname>von Kanel</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>The association between inflammatory biomarkers and metabolically healthy obesity depends of the definition used</article-title>. <source>Eur J Clin Nutr</source> <volume>66</volume>: <fpage>426</fpage>–<lpage>435</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Zimmet1"><label>57</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zimmet</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Boyko</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Collier</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>de Courten</surname><given-names>M</given-names></name> (<year>1999</year>) <article-title>Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players</article-title>. <source>Ann N Y Acad Sci</source> <volume>892</volume>: <fpage>25</fpage>–<lpage>44</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-VuksanCusa1"><label>58</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vuksan-Cusa</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Sagud</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jakovljevic</surname><given-names>M</given-names></name> (<year>2010</year>) <article-title>C-reactive protein and metabolic syndrome in patients with bipolar disorder compared to patients with schizophrenia</article-title>. <source>Psychiatr Danub</source> <volume>22</volume>: <fpage>275</fpage>–<lpage>277</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Saltevo1"><label>59</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saltevo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vanhala</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kautiainen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Laakso</surname><given-names>M</given-names></name> (<year>2007</year>) <article-title>Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with the relative change in body mass index between childhood and adulthood</article-title>. <source>Diab Vasc Dis Res</source> <volume>4</volume>: <fpage>328</fpage>–<lpage>331</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Grundy1"><label>60</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grundy</surname><given-names>SM</given-names></name> (<year>1999</year>) <article-title>Hypertriglyceridemia, insulin resistance, and the metabolic syndrome</article-title>. <source>Am J Cardiol</source> <volume>83</volume>: <fpage>25F</fpage>–<lpage>29F</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Laaksonen1"><label>61</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Laaksonen</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Niskanen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Nyyssonen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Punnonen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tuomainen</surname><given-names>TP</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men</article-title>. <source>Diabetologia</source> <volume>47</volume>: <fpage>1403</fpage>–<lpage>1410</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Verma1"><label>62</label>
<mixed-citation publication-type="other" xlink:type="simple">Verma S, Yeh ET (2003) C-reactive protein and atherothrombosis–beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol 285: R1253–1256; discussion R1257–1258.</mixed-citation>
</ref>
<ref id="pone.0066847-MohamedAli1"><label>63</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mohamed-Ali</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Goodrick</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rawesh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Katz</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Miles</surname><given-names>JM</given-names></name>, <etal>et al</etal>. (<year>1997</year>) <article-title>Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo</article-title>. <source>J Clin Endocrinol Metab</source> <volume>82</volume>: <fpage>4196</fpage>–<lpage>4200</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Hsuchou1"><label>64</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hsuchou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kastin</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Mishra</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>W</given-names></name> (<year>2012</year>) <article-title>C-Reactive Protein Increases BBB Permeability: Implications for Obesity and Neuroinflammation</article-title>. <source>Cell Physiol Biochem</source> <volume>30</volume>: <fpage>1109</fpage>–<lpage>1119</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Zhu1"><label>65</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhu</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Blakely</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Hewlett</surname><given-names>WA</given-names></name> (<year>2006</year>) <article-title>The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters</article-title>. <source>Neuropsychopharmacology</source> <volume>31</volume>: <fpage>2121</fpage>–<lpage>2131</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Alessi1"><label>66</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alessi</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Bastelica</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Morange</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Berthet</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Leduc</surname><given-names>I</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity</article-title>. <source>Diabetes</source> <volume>49</volume>: <fpage>1374</fpage>–<lpage>1380</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Porreca1"><label>67</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Porreca</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Di Febbo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vitacolonna</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Baccante</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Di Castelnuovo</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Transforming growth factor-beta1 levels in hypertensive patients: association with body mass index and leptin</article-title>. <source>Am J Hypertens</source> <volume>15</volume>: <fpage>759</fpage>–<lpage>765</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Grainger1"><label>68</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grainger</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Kemp</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Metcalfe</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Lawn</surname><given-names>RM</given-names></name>, <etal>et al</etal>. (<year>1995</year>) <article-title>The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis</article-title>. <source>Nat Med</source> <volume>1</volume>: <fpage>74</fpage>–<lpage>79</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Majesky1"><label>69</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Majesky</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Lindner</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Twardzik</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Schwartz</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Reidy</surname><given-names>MA</given-names></name> (<year>1991</year>) <article-title>Production of transforming growth factor beta 1 during repair of arterial injury</article-title>. <source>J Clin Invest</source> <volume>88</volume>: <fpage>904</fpage>–<lpage>910</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Massague1"><label>70</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Massague</surname><given-names>J</given-names></name> (<year>1990</year>) <article-title>The transforming growth factor-beta family</article-title>. <source>Annu Rev Cell Biol</source> <volume>6</volume>: <fpage>597</fpage>–<lpage>641</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Wang1"><label>71</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>XL</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>SX</given-names></name>, <name name-style="western"><surname>Wilcken</surname><given-names>DE</given-names></name> (<year>1997</year>) <article-title>Circulating transforming growth factor beta 1 and coronary artery disease</article-title>. <source>Cardiovasc Res</source> <volume>34</volume>: <fpage>404</fpage>–<lpage>410</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Moon1"><label>72</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moon</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>DK</given-names></name> (<year>2004</year>) <article-title>Serum tumor necrosis factor-alpha levels and components of the metabolic syndrome in obese adolescents</article-title>. <source>Metabolism</source> <volume>53</volume>: <fpage>863</fpage>–<lpage>867</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Brietzke2"><label>73</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brietzke</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Stertz</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fernandes</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Kauer-Sant'anna</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mascarenhas</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder</article-title>. <source>J Affect Disord</source> <volume>116</volume>: <fpage>214</fpage>–<lpage>217</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Pan1"><label>74</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pan</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Kastin</surname><given-names>AJ</given-names></name> (<year>1999</year>) <article-title>Penetration of neurotrophins and cytokines across the blood-brain/blood-spinal cord barrier</article-title>. <source>Adv Drug Deliv Rev</source> <volume>36</volume>: <fpage>291</fpage>–<lpage>298</lpage>.</mixed-citation>
</ref>
<ref id="pone.0066847-Goldberg1"><label>75</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goldberg</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Perlis</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Bowden</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Thase</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Miklowitz</surname><given-names>DJ</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD</article-title>. <source>Am J Psychiatry</source> <volume>166</volume>: <fpage>173</fpage>–<lpage>181</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>